- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Suven Life Sciences Limited — Updates, 22-06-2026: Press Release
22-06-2026 | 10:23 am
22-06-2026 | 10:23 am
Suven Life Sciences is showcasing its advanced CNS drug pipeline at BIO-2026, including late-stage assets Ropanicant (MDD), Masupirdine (Alzheimer's agitation), and Samelisant (Narcolepsy). The company aims to explore partnering for development and commercialization of its portfolio.
No comments yet. Be the first to comment!